Market Closed -
Nasdaq
01:30:00 09/05/2024 am IST
5-day change
1st Jan Change
67.54
USD
-1.60%
-4.40%
-8.22%
This article is reserved for members
Not a member ?
Free registration
Nuvalent Insider Sold Shares Worth $2,605,525, According to a Recent SEC Filing
09/05
MT
Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing
02/05
MT
Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing
18/04
MT
Jefferies Initiates Nuvalent With Buy Rating, $97 Price Target
17/04
MT
Nuvalent Insider Sold Shares Worth $2,566,479, According to a Recent SEC Filing
11/04
MT
North American Morning Briefing : Stocks Seen -2-
02/04
DJ
Nuvalent Insider Sold Shares Worth $1,654,311, According to a Recent SEC Filing
01/04
MT
Leerink Partners Upgrades Nuvalent to Outperform From Market Perform, Raises Price Target to $110 From $69
01/04
MT
Nuvalent Insider Sold Shares Worth $3,032,528, According to a Recent SEC Filing
28/03
MT
Nuvalent Insider Sold Shares Worth $1,550,229, According to a Recent SEC Filing
26/03
MT
BMO Capital Raises Price Target on Nuvalent to $102 From $93, Maintains Outperform Rating
28/02
MT
Nuvalent's Non-Small Cell Lung Cancer Drug Candidate Gets FDA Breakthrough Therapy Designation
27/02
MT
Nuvalent, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
27/02
CI
Nuvalent, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
27/02
CI
Baird Initiates Nuvalent With Outperform Rating, Price Target is $105
23/02
MT
Nuvalent Starts Phase 2 Part of Clinical Trial of Potential Lung Cancer Treatment
12/02
MT
Wedbush Raises Nuvalent's Price Target to $99 From $82, Maintains Outperform Rating
12/02
MT
Nuvalent, Inc. Initiates the Phase 2 Portion of Alkove-1 Clinical Trial for Patients with Alk-Positive Nsclc and Other Solid Tumors
12/02
CI
Nuvalent Outlines Three-Year Product Plan
08/01
MT
Wedbush Raises Nuvalent's PT to $82 From $74 After Announced 3-Year Plan to Place At Least One Lead Asset on Market by 2026; Keeps Outperform Rating
08/01
MT
Nuvalent Insider Sold Shares Worth $378,350, According to a Recent SEC Filing
21/12
MT
Nuvalent Insider Sold Shares Worth $2,274,600, According to a Recent SEC Filing
21/12
MT
Nuvalent Insider Sold Shares Worth $2,880,548, According to a Recent SEC Filing
21/12
MT
Nuvalent Insider Sold Shares Worth $3,032,800, According to a Recent SEC Filing
21/12
MT
Certain Class A Common Stock of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2023.
16/12
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.
More about the company
Last Close Price
67.54
USD
Average target price
101.1
USD
Spread / Average Target
+49.71%
Consensus
1st Jan change
Capi.
-8.22% 4.43B +22.56% 46.4B -1.51% 41.75B +48.83% 41.37B -3.42% 29.71B +10.13% 26.01B -20.44% 19.52B +26.45% 12.43B -0.14% 12.18B -0.47% 12.13B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1